secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092722
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M
---------------------------------------------------------------------------

- Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).
- Gross margin 78.4% vs 72.7% Q2 2023; net loss improved 19% to $10.8M; Adjusted EBITDA loss improved 38% to $5.6M.
- Raises full-year 2024 revenue guidance to $70-72M from prior $65-68M.
- Lung diagnostic test volume 13,900, up 42% YoY and 17% sequentially.
- Cash $42.2M at June 30, 2024, including $55M from April stock offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024092722/0000950170-24-092722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017024092722/bdsx-20240807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer